TKIs targeting the vascular endothelial growth factor receptor (VEGFR-TKIs), such as sunitinib, ponatinib, pazopanib and sorafenib are commonly associated with severe hypertension as well as the anti-VEGF monoclonal antibody bevacizumab [73–78]. This evidence concerns the gene KDR and Hypertension.